27.06.2022
The social costs of severe haemophilia A and B in adults in Switzerland
Haemophilia is a rare genetic blood coagulation disorder. It (almost) exclusively affects men. Affected persons bleed longer after injuries or suffer spontaneous bleeding even with little exertion. There are two main types in haemophilia: haemophilia A and B.
We have calculated the social costs of severe haemophilia in adults in Switzerland for the first time. We determined the direct, indirect and intangible costs for haemophilia A and B, respectively. Wherever possible, we referred to Swiss data sources. Alternatively, we used information from international literature.
We estimate the social costs of severe haemophilia in 2020 to be around CHF 55 million, with 93%, or CHF 51 million, being factor therapy costs, in other words the replacement of the insufficiently produced coagulation factor. At a total of CHF 2.9 million, the indirect costs were relatively low compared with the total costs.
Link to the publication We have calculated the social costs of severe haemophilia in adults in Switzerland for the first time. We determined the direct, indirect and intangible costs for haemophilia A and B, respectively. Wherever possible, we referred to Swiss data sources. Alternatively, we used information from international literature.
We estimate the social costs of severe haemophilia in 2020 to be around CHF 55 million, with 93%, or CHF 51 million, being factor therapy costs, in other words the replacement of the insufficiently produced coagulation factor. At a total of CHF 2.9 million, the indirect costs were relatively low compared with the total costs.